Skip to main content

An open-label, randomized, phase 2 Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- or high-riskdiffuse large B-cell lymphoma.


AUTHORS

Hainsworth JD , Arrowsmith ER , McCleod M , Hsi ED , Hamid O , Shi P , Lin BK , Fayad LE , . Leukemia & lymphoma. 2015 5 8; (). 1-11

ABSTRACT



Tags: